Novo Nordisk Partners with Vivtex for Oral Obesity Drugs in $2.1 Billion Deal

Novo Nordisk has entered into a partnership with Vivtex in a deal potentially worth up to $2.1 billion, focusing on the development of new oral obesity drugs.